InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

Rhea-AI Summary

InflaRx (IFRX) reported key achievements for 2024 and milestones for 2025. The company received European Commission approval for GOHIBIC® (vilobelimab) to treat SARS-CoV-2-induced ARDS. They reached a 30-patient recruitment milestone in Phase 3 vilobelimab trial for pyoderma gangrenosum, with interim analysis expected by May 2025.

Financial highlights include:

• Cash position of €55.2 million as of December 31, 2024
• Additional €28.7 million raised through public offering in February 2025
• Cash runway extended into 2027
• Net loss of €46.1 million (€0.78 per share) in 2024
• R&D expenses decreased to €35.4 million

The company dosed first patient in Phase 2a trial for oral C5aR inhibitor INF904, with topline data in chronic spontaneous urticaria and hidradenitis suppurativa expected in summer 2025. Multiple data presentations at AAD 2025 highlighted vilobelimab's potential in reducing systemic inflammation.

Positive

• European Commission approval for GOHIBIC® (vilobelimab) for SARS-CoV-2-induced ARDS
• Successful €28.7M fundraising through public offering
• Cash runway extended into 2027
• R&D expenses decreased by €5.7M to €35.4M
• Potential €1B+ market opportunity for each indication (CSU and HS) with INF904

Negative

• Net loss increased to €46.1M in 2024 from €42.7M in 2023
• Marketing and sales expenses increased by €2.8M
• Cost of sales increased by €2.8M due to inventory write-downs
• Low product revenue of only €0.2M from GOHIBIC sales

Insights

Biotech Financial Analyst

InflaRx's year-end results reveal a strategic advancement phase with significant regulatory success and pipeline progression, despite widening losses. The EU approval for GOHIBIC (vilobelimab) represents their first marketed product in Europe for SARS-CoV-2-induced ARDS, creating potential future revenue streams, though commercialization partnerships would be needed to realize this potential.

The company's financial position shows strengthening, with €55.2 million in cash at year-end, bolstered by an additional €28.7 million raised in February 2025. This extends their runway into 2027, providing critical operational stability through multiple clinical readouts. However, the €46.1 million net loss (versus €42.7 million in 2023) highlights ongoing cash burn challenges typical for clinical-stage biotechs.

Two key catalysts warrant investor attention: the upcoming interim analysis for the Phase 3 vilobelimab PG trial expected by May 2025, and summer 2025 topline data from the Phase 2a trial of oral C5aR inhibitor INF904 in CSU and HS. Both represent potential inflection points, particularly as the company estimates these indications could each represent addressable markets exceeding $1 billion.

R&D expense reduction to €35.4 million (down €5.7 million) demonstrates improved operational efficiency, though increased marketing expenses of €2.8 million and inventory write-downs of €2.8 million partially offset these gains. Current product revenue remains minimal at just €0.2 million, emphasizing that InflaRx remains primarily a development-stage company despite having approved products.

Pharmaceutical Development Specialist

InflaRx's complement pathway inhibitor portfolio shows promising clinical development momentum. The European Commission approval for GOHIBIC (vilobelimab) marks a significant regulatory achievement as the first approved treatment for SARS-CoV-2-induced ARDS in the EU. This validates their C5a inhibition approach while creating a template for potential future approvals.

Their pyoderma gangrenosum (PG) program has reached a critical juncture with the 30-patient recruitment milestone enabling an interim analysis by May 2025. This adaptive trial design is strategically sound for a rare disease indication, allowing for sample size adjustments based on observed treatment effects, potentially accelerating development timelines while controlling costs.

The oral C5aR inhibitor INF904 represents InflaRx's next-generation approach, with potential advantages in dosing convenience and possibly differentiated efficacy. The Phase 2a basket trial design in CSU and HS is efficient, examining both safety/PK and preliminary efficacy signals simultaneously across multiple indications. The 4-week treatment period should provide sufficient data to inform future development, though longer treatment duration would be needed to fully assess chronic treatment potential.

Multiple AAD presentations highlighting vilobelimab's potential in reducing systemic inflammation reinforce the broader applicability of their complement inhibition platform. The selection by BARDA for inclusion in their ARDS platform study provides additional validation and potential for expanded indications beyond COVID-19, supporting the company's scientific approach and potentially broadening future market opportunities.

• Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome (ARDS)
• Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG) to enable an expected interim analysis for trial size adaptation or futility by the end of May 2025
• Dosed first patient in Phase 2a trial for oral C5aR inhibitor, INF904, with topline data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected in summer 2025
• Multiple data presentations at AAD 2025 highlighting the potential of vilobelimab in reducing systemic inflammation
• Cash, cash equivalents and marketable securities of €55.2 million as of December 31, 2024
• Additional €28.7 million ($30.0 million) in gross proceeds subsequently raised by an underwritten public offering of ordinary shares and pre-funded warrants on February 18, 2025
• InflaRx’s cash runway significantly extended, with sufficient cash, cash equivalents and marketable securities to fund currently planned operations into 2027
  

JENA, Germany, March 20, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its financial results for the year ended December 31, 2024, highlighting recent operational achievements and expected milestones for 2025.

Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, commented: “2024 was a highly productive year for InflaRx, with the company achieving all major development and regulatory goals across its pipeline programs and making meaningful progress in addressing critical medical needs in inflammatory diseases.” He continued: “We look forward to a catalyst-rich year in 2025 as we continue to advance our pipeline, including reaching the interim analysis for the Phase 3 trial with vilobelimab in pyoderma gangrenosum and reporting top-line Phase 2a data in chronic spontaneous urticaria and hidradenitis suppurativa with INF904, our oral C5aR inhibitor with best-in-class potential."

Select recent highlights and expected milestones

INF904 in CSU and HS – Topline Phase 2a data expected in summer 2025

In December 2024, InflaRx announced that the first patient had been dosed in its Phase 2a basket study with INF904 in CSU and HS. This is a multi-center, open-label study evaluating multiple INF904 dosing regimens over 4 weeks of treatment in a total of 75 patients (45 in CSU and 30 in HS). The goal of the trial is to generate additional safety and pharmacokinetic (PK) data and to provide signs of clinical benefit. After the 4-week treatment period, patients will be followed for an additional 4 weeks. Topline data from this study are expected in the summer of 2025, with a goal of informing the planning and design of a larger, longer-term Phase 2b study by year-end 2025.

InflaRx believes CSU and HS each has potential addressable markets of $1 billion or more for INF904. The Company also believes INF904 could address meaningful opportunities in additional immuno-dermatology and immuno-inflammatory indications, including in nephrology, neurology and hematology. While InflaRx intends to focus its resources on its immediate goals addressing CSU and HS, the Company continues to assess and monitor the value of pursuing additional areas and applications via potential future collaborations with partners.

Vilobelimab in PG – Pivotal Phase 3 trial interim analysis expected by the end of May 2025

In November 2024, InflaRx announced that it had achieved the 30-patient recruitment milestone in its ongoing Phase 3 vilobelimab trial in PG. This is expected to enable the interim analysis for trial size adaptation or futility by the end of May 2025. Trial enrollment continues. The study dosed its first patient in November 2023 and has an adaptive design with an interim analysis (unblinded only for the independent data monitoring committee), which is planned when 30 patients randomized 1:1 to the two arms have completed treatment. The interim analysis with a set of predefined rules will consider the then-observed difference in complete target ulcer closure between the two arms and will then determine whether the trial sample size will be adapted or whether the trial should be stopped due to futility. The enrollment period is projected to last at least two years, and its overall period will depend on the total trial size after sample size adaptation.

The Phase 3 trial is a multi-national, randomized, double-blind, placebo-controlled pivotal study assessing the benefit of vilobelimab for treating ulcerative PG, a rare, chronic inflammatory form of neutrophilic dermatosis characterized by accumulation of neutrophils in the affected skin areas. The trial has two arms: (1) vilobelimab plus a low dose of corticosteroids and (2) placebo plus the same dose of corticosteroids, both tapered over an 8-week period. The primary endpoint of the study is complete closure of the target ulcer measured at two consecutive visits at any time up to 26 weeks after initiation of treatment.

Vilobelimab has been granted orphan drug designation for the treatment of PG by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), as well as fast track designation by the FDA.

Vilobelimab presentations at the 2025 AAD Annual Meeting

During the 2025 American Academy of Dermatology (AAD) Annual Meeting held March 7 – 11 in Orlando, FL, vilobelimab was featured in multiple sessions. Collectively, these data highlighted the utility of vilobelimab in treating multiple inflammatory conditions, including PG and HS, with supporting evidence from clinical efficacy data, safety assessments, and pharmacokinetic and pharmacodynamic analyses.

GOHIBIC (vilobelimab) granted EU marketing authorization

In January 2025, the European Commission (EC) granted marketing authorization under exceptional circumstances for GOHIBIC (vilobelimab) for the treatment of adult patients with SARS-CoV-2-induced ARDS who are receiving systemic corticosteroids as part of standard of care and receiving invasive mechanical ventilation (IMV) with or without extracorporeal membrane oxygenation (ECMO). GOHIBIC (vilobelimab) is the first and only treatment approved in the European Union (EU) for the treatment of SARS-CoV-2-induced ARDS.

The marketing authorization under exceptional circumstances for GOHIBIC (vilobelimab) is valid in all 27 EU member states as well as Iceland, Liechtenstein, and Norway. InflaRx is considering commercial partnering and distribution options in the EU and does not expect this approach will have a materially negative impact on its cash burn rate.

In June 2024, InflaRx announced that GOHIBIC (vilobelimab) had been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, as one of three investigational therapies to be assessed in a Phase 2 clinical platform study exploring potential new options for the treatment of ARDS. Vilobelimab is one of three host-directed investigational drugs assessed in this study, with the safety and efficacy of each investigational drug to be studied in its own patient cohort and compared against placebo. This Phase 2 platform study is expected to collect data in order to define subsets of patients with ARDS who may benefit from specific host-directed therapeutics and to inform the design of potential Phase 3 studies.

Dr. Thomas Taapken, Chief Financial Officer of InflaRx, said: “With our recent successful capital raise and the efficient utilization of our balance sheet, InflaRx is on solid financial footing, enabling us to efficiently advance our key development programs. Importantly, our cash runway into 2027 should allow us to reach several value inflection points, including the end-of-May interim analysis for the vilobelimab Phase 3 study in pyoderma gangrenosum, along with the eventual readout of this trial, as well as the INF904 Phase 2a topline data this summer.”

Financing activities

In February 2025, the company completed an underwritten public offering of ordinary shares and pre-funded warrants leading to gross proceeds from the offering of €28.7 million ($30.0 million), before deducting the underwriting discount and offering expenses.

2024 Financial highlights
Revenue

In 2024, we realized revenues from product sales of GOHIBIC (vilobelimab) in the amount of €0.2 million, which represents an increase of €0.1 million compared to the prior year. Revenues reported are sales to end customers (hospitals). Sales to distributors do not constitute revenue for the Company. All revenues are attributed to sales made in the United States.

Cost of sales

Cost of sales increased by €2.8 million in 2024 compared to the corresponding costs for 2023, primarily due to higher inventory write-downs of €2.8 million as a result of quantities on hand exceeding quantities expected to be sold prior to expiry.

Marketing and sales expenses

Marketing and sales expenses increased by €2.8 million in 2024 compared to 2023, as 2024 represented the first full year of commercial efforts for GOHIBIC (vilobelimab) in the United States. In 2023, marketing and sales expenses were only incurred during the second half of the year.

Research and development expenses

Research and development expenses decreased by €5.7 million to €35.4 million in 2024 compared to the year 2023. This decrease was primarily attributable to €8.7 million lower third-party costs from manufacturing development activities and from clinical trials, offset by €1.6 million higher personnel expenses and €1.4 million higher other expenses compared to the previous year. Other expenses include a one-off milestone contractual payment of $1.0 million (€1.0 million) relating to market authorization for GOHIBIC (vilobelimab) in the EU.

General and administrative expenses

General and administrative expenses increased by €0.4 million to €13.0 million for the year ended December 31, 2024, from €12.6 million for the year ended December 31, 2023. This increase is comprised of higher personnel expenses of €0.9 million and partially offset by a decrease in legal and consulting expenses of €0.4 million and a decrease in insurance expenses of €0.4 million.

Other income

Other income decreased by €7.9 million in 2024 compared to the year 2023 due primarily to lower income from government grants. In June 2023, our grant from the German Ministry of Education and Research and the German Ministry of Health to support the development of vilobelimab for the treatment of severe COVID-19 patients ended. In 2024, upon qualifying for an allowance under the German Research Allowance Act, we recognized €5.1 million in income relating to expenses, eligible for reimbursement, which were incurred in the years 2020 to 2024. We remain eligible for additional research allowances for eligible expenses to be incurred from 2025 to 2027.

Net financial result

Net financial result increased by €4.7 million to a gain of €6.9 million in 2024 compared to €2.2 million in 2023. This overall net increase is mainly attributable to an increase of €5.5 million in foreign exchange results, partially offset by €0.6 million lower interest income from marketable securities compared to 2023.

Net loss

We incurred a net loss of €46.1 million, or €0.78 per ordinary share, in 2024, compared to €42.7 million, or €0.78 per ordinary share, in 2023.

Liquidity and capital resources

As of December 31, 2024, our total funds available amounted to approximately €55.2 million, comprised of €18.4 million of cash and cash equivalents and €36.8 million of marketable securities.

Net cash used in operating activities

Net cash used in operating activities increased to €48.6 million in 2024, from €37.8 million in 2023, mainly due to lower income recognized from German federal government grants and research allowances

Additional financial information

Additional information regarding these results and other relevant information is included in the notes to the financial statements in “Item 18. Financial Statements”, which are included in InflaRx’s most recent annual report on Form 20-F as filed today with the U.S. Securities and Exchange Commission (SEC).

InflaRx N.V. and subsidiaries
Consolidated statements of operations and comprehensive loss
for the years ended December 31, 2024, 2023 and 2022

		2024			2023			2022
		(in €, except for share data)
Revenues		165,789			63,089			—
Cost of sales		(3,317,039	)		(532,262	)		—
Gross profit		(3,151,250	)		(469,173	)		—
Marketing and sales expenses		(6,756,595	)		(4,001,299	)		—
Research and development expenses		(35,363,897	)		(41,024,131	)		(37,526,090	)
General and administrative expenses		(13,024,441	)		(12,628,756	)		(14,869,564	)
Other income		5,287,616			13,219,704			20,159,169
Other expenses		(297	)		(4,440	)		(1,381	)
Operating result		(53,008,864	)		(44,908,096	)		(32,237,866	)
Finance income		3,196,813			3,804,827			608,679
Finance expenses		(20,655	)		(35,628	)		(45,250	)
Foreign exchange result		3,670,235			(1,841,872	)		2,442,297
Other financial result		103,285			313,240			(252,471	)
Income taxes		(5,217	)		—			—
Loss for the period		(46,064,402	)		(42,667,529	)		(29,484,611	)
Other comprehensive income (loss) that may be reclassified to profit or loss in subsequent periods:
Exchange differences on translation of foreign currency		58,344			125,085			4,206,810
TOTAL COMPREHENSIVE LOSS		(46,006,058	)		(42,542,444	)		(25,277,801	)
Share information
Weighted average number of shares outstanding		58,918,678			54,940,137			44,207,873
Loss per share (basic/diluted)		(0.78	)		(0.78	)		(0.67	)

InflaRx N.V. and subsidiaries
Consolidated statements of financial position as of December 31, 2024 and 2023

		December 31, 2024			December 31, 2023
ASSETS		(in €)
Non-current assets
Property and equipment		256,280			289,577
Right-of-use assets		758,368			1,071,666
Intangible assets		50,781			68,818
Other assets		204,233			257,267
Financial assets		3,092,290			9,052,741
Total non-current assets		4,361,952			10,740,069
Current assets
Inventories		6,897,666			11,367,807
Current other assets		5,103,402			4,036,649
Other assets from government grants and research allowance		5,081,772			—
Tax receivable		1,735,335			3,791,564
Other financial assets		34,462,352			77,504,518
Cash and cash equivalents		18,375,979			12,767,943
Total current assets		71,656,505			109,468,482
TOTAL ASSETS		76,018,457			120,208,551
EQUITY AND LIABILITIES
Equity
Issued capital		7,122,205			7,065,993
Share premium		334,929,685			334,211,338
Other capital reserves		44,115,861			40,050,053
Accumulated deficit		(332,192,221	)		(286,127,819	)
Other components of equity		7,440,510			7,382,166
Total equity		61,416,039			102,581,730
Non-current liabilities
Lease liabilities		399,066			745,716
Other liabilities		36,877			36,877
Total non-current liabilities		435,943			782,593
Current liabilities
Trade and other payables		11,394,232			11,974,362
Lease liabilities		406,020			374,329
Employee benefits		2,064,678			1,609,766
Other liabilities		301,544			2,885,772
Total current liabilities		14,166,475			16,844,228
Total liabilities		14,602,417			17,626,822
TOTAL EQUITY AND LIABILITIES		76,018,457			120,208,552

InflaRx N.V. and subsidiaries
Consolidated statements of changes in shareholders’ equity
for the years ended December 31, 2024, 2023 and 2022

in €	Issued capital		Share pre­mium			Other capital reserves		Ac­cu­mu­lated deficit			Other com­­po­nents of equity		Total equity
Balance as of January 01, 2022	5,304,452		280,310,744			30,591,209		(213,975,679	)		3,050,270		105,280,996
Loss for the Period	—		—			—		(29,484,611	)		—		(29,484,611	)
Exchange differences on translation of foreign currency	—		—			—		—			4,206,810		4,206,810
Total Comprehensive Loss	—		—			—		(29,484,611	)		4,206,810		(25,277,801	)
Issuance of ordinary shares	60,000		2,289,624			—		—			—		2,349,624
Transaction costs	—		(47,735	)		—		—			—		(47,735	)
Equity-settled share-based pay­ments	—		—			6,044,356		—			—		6,044,356
Balance as of December 31, 2022	5,364,452		282,552,633			36,635,564		(243,460,290	)		7,257,080		88,349,440
Loss for the Period	—		—			—		(42,667,529	)		—		(42,667,529	)
Exchange differences on translation of foreign currency	—		—			—		—			125,085		125,085
Total Comprehensive Loss	—		—			—		(42,667,529	)		125,085		(42,542,444	)
Issuance of ordinary shares	1,687,110		54,796,819			—		—			—		56,483,929
Transaction costs	—		(3,360,626	)		—		—			—		(3,360,626	)
Equity-settled share-based pay­ments	—		—			3,414,489		—			—		3,414,489
Share options exercised	14,431		222,512			—		—			—		236,943
Balance as of December 31, 2023	7,065,993		334,211,338			40,050,053		(286,127,819	)		7,382,166		102,581,730
Loss for the Period	—		—			—		(46,064,402	)		—		(46,064,402	)
Exchange differences on translation of foreign currency	—		—			—		—			58,344		58,344
Total Comprehensive Loss	—		—			—		(46,064,402	)		58,344		(46,006,058	)
Issuance of ordinary shares	56,213		1,042,076			—		—			—		1,098,289
Transaction costs	—		(323,729	)		—		—			—		(323,729	)
Equity-settled share-based pay­ments	—		—			4,065,807		—			—		4,065,807
Balance as of December 31, 2024	7,062,206		334,929,685			44,115,861		(332,192,221	)		7,440,510		61,416,039

InflaRx N.V. and subsidiaries
Consolidated statements of cash flows
for the years ended December 31, 2024, 2023 and 2022

		2024			2023			2022
		(in €)
Operating activities
Loss for the period		(46,064,402	)		(42,667,529	)		(29,484,611	)
Adjustments for:
Depreciation & amortization of property and equipment, right-of-use assets and intangible assets		485,114			567,780			596,597
Net finance income		(6,949,679	)		(2,240,566	)		(2,753,255	)
Share-based payment expense		4,065,807			3,414,489			6,044,356
Net foreign exchange differences		(37,101	)		413,017			385,359
Changes in:
Other assets from government grants and research allowances		(5,081,772	)		732,971			(732,971	)
Other assets		1,042,513			7,825,181			(3,308,485	)
Employee benefits		454,912			297,518			(64,024	)
Other liabilities		(2,584,228	)		2,738,164			9,403
Liabilities from government grants received		—			(6,209,266	)		(2,090,734	)
Trade and other payables		(580,129	)		6,986,824			(3,586,706	)
Inventories		4,470,141			(11,367,807	)		—
Interest received		2,243,197			1,732,284			1,287,200
Interest paid		(21,064	)		(36,025	)		(44,946	)
Net cash used in operating activities		(48,556,690	)		(37,812,966	)		(33,742,817	)
Investing activities
Purchase of intangible assets and property and equipment		(46,871	)		(81,100	)		(162,391	)
Purchase of current and non-current financial assets		(35,340,107	)		(104,051,972	)		(64,474,543	)
Proceeds from the maturity of current financial assets		87,751,331			86,436,456			83,995,029
Net cash from/ (used in) investing activities		52,364,354			(17,696,616	)		19,358,095
Financing activities
Proceeds from issuance of ordinary shares		1,098,289			56,483,929			2,349,624
Transaction costs from issuance of ordinary shares		(323,729	)		(3,360,626	)		(47,735	)
Proceeds from exercise of share options		—			236,943			—
Repayment of lease liabilities		(388,114	)		(373,977	)		(364,430	)
Net cash from financing activities		386,446			52,986,269			1,937,459
Net in-/decrease in cash and cash equivalents		4,194,110			(2,523,313	)		(12,447,262	)
Effect of exchange rate changes on cash and cash equivalents		1,413,926			(974,099	)		2,462,622
Cash and cash equivalents at beginning of period		12,767,943			16,265,355			26,249,995
Cash and cash equivalents at end of period		18,375,979			12,767,943			16,265,355

About GOHIBIC (vilobelimab)

In the EU, GOHIBIC (vilobelimab) has been granted marketing authorization under exceptional circumstances for the treatment of adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids as part of standard of care and receiving invasive mechanical ventilation (IMV) (with or without extracorporeal membrane oxygenation (ECMO)). The EU approval of GOHIBIC (vilobelimab) is supported by the previously announced results of the multicenter Phase 3 PANAMO trial, one of the largest 1:1 randomized, double-blind, placebo-controlled trials in invasively mechanically ventilated COVID-19 patients in intensive care units. The results showed that vilobelimab treatment improved survival with a relative reduction in 28-day all-cause mortality of 23.9% compared to placebo in the global data set. The data were published in The Lancet Respiratory Medicine.

A marketing authorization under exceptional circumstances is recommended when the benefit/risk assessment is determined to be positive but, due to the rarity of the disease, it’s unlikely that comprehensive data can be obtained under normal conditions of use. Under the terms of GOHIBIC (vilobelimab)’s approval in the EC, InflaRx will provide annual updates to EMA on the previously announced clinical platform study planned by the Biomedical Advanced Research and Development Authority (BARDA). Vilobelimab is included in this study as one of three new potential therapies for treating ARDS.

In the U.S., GOHIBIC (vilobelimab) has been granted an Emergency Use Authorization by the Food and Drug Administration (FDA) for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving IMV or ECMO. The emergency use of GOHIBIC (vilobelimab) is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated, or authorization revoked sooner.

GOHIBIC (vilobelimab) is an investigational drug that has not been approved by the FDA for any indication, including for the treatment of COVID-19. There is limited information known about the safety and effectiveness of using GOHIBIC (vilobelimab) to treat people in the hospital with COVID-19. Please see additional information in the Fact Sheet for Healthcare Providers, Fact Sheet for Patients and Parents/Caregivers and FDA Letter of Authorization on the GOHIBIC (vilobelimab) website http://www.gohibic.com.

Important Safety Information about GOHIBIC (vilobelimab)

There are limited clinical data available for GOHIBIC (vilobelimab). Serious and unexpected adverse events (AEs) may occur that have not been previously reported with GOHIBIC (vilobelimab) use.

GOHIBIC (vilobelimab) has been associated with an increase of serious infections. In patients with COVID-19, monitor for signs and symptoms of new infections during and after treatment with GOHIBIC (vilobelimab). Hypersensitivity reactions have been observed with GOHIBIC (vilobelimab). If a severe hypersensitivity reaction occurs, administration of GOHIBIC (vilobelimab) should be discontinued and appropriate therapy initiated.

The most common adverse reactions (incidence ≥3%) are pneumonia, sepsis, delirium, pulmonary embolism, hypertension, pneumothorax, deep vein thrombosis, herpes simplex, enterococcal infection, bronchopulmonary aspergillosis, hepatic enzyme increased, urinary tract infection, hypoxia, thrombocytopenia, pneumomediastinum, respiratory tract infection, supraventricular tachycardia, constipation, and rash.

Healthcare providers and/or their designee are responsible for mandatory FDA MedWatch reporting of all medication errors and serious AEs or deaths that occur during GOHIBIC (vilobelimab) treatment and are considered to be potentially attributable to GOHIBIC (vilobelimab).

Report side effects to the FDA at 1-800-FDA-1088 or www.FDA.gov/medwatch. In addition, side effects can be reported to InflaRx at: pvusa@inflarx.de.

For the full prescribing information and additional important safety information, please visit www.GOHIBIC.com.

The COVID-19 related work described herein was partly funded by the German Federal Government through grant number 16LW0113 (VILO-COVID). All responsibility for the content of this work lies with InflaRx.

About vilobelimab

Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood. Thus, vilobelimab leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism of the innate immune system, which is not the case for molecules blocking C5. In pre-clinical studies, vilobelimab has been shown to control the inflammatory response-driven tissue and organ damage by specifically blocking C5a as a key “amplifier” of this response.

Vilobelimab is being developed for various debilitating or life-threatening inflammatory indications, including pyoderma gangrenosum (PG). Vilobelimab has been granted orphan drug designation for the treatment of PG by both the FDA and the EMA, as well as fast track designation by the FDA.

About INF904

INF904 is an orally administered, small molecule inhibitor of the C5a receptor that has shown anti-inflammatory therapeutic effects in several pre-clinical disease models. Further, in contrast to the marketed C5aR inhibitor, in vitro experiments demonstrated that INF904 has minimal inhibition of the cytochrome P450 3A4/5 (CYP3A4/5) enzymes, which play an important role in the metabolism of a variety of metabolites and drugs, including glucocorticoids. Reported results from a first-in-human study demonstrated that INF904 is well tolerated in treated subjects and exhibits no safety signals of concern in single doses ranging from 3 mg to 240 mg or multiple doses ranging from 30 mg once per day (QD) to 90 mg twice per day (BID) for 14 days. PK / pharmacodynamic data support the best-in-class potential of INF904 with a ≥90% blockade of C5a-induced neutrophil activation achieved over the 14-day dosing period.

About InflaRx N.V.

InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).

InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor.  InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de.

Contacts:

InflaRx N.V.	MC Services AG
Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de	Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752

_{* Eligibility Requirements, Terms and Conditions apply. Please see the full Terms and Conditions provided on the webpage: The InflaRx Commitment Program.}

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, the receptiveness of GOHIBIC (vilobelimab) as a treatment for COVID-19 by COVID-19 patients and U.S. hospitals and related treatment recommendations by medical/healthcare institutes and other third-party organizations, our ability to successfully commercialize and the receptiveness of GOHIBIC (vilobelimab) as a treatment for COVID-19 by COVID-19 patients and U.S. hospitals or our other product candidates; our expectations regarding the size of the patient populations for, market opportunity for, coverage and reimbursement for, estimated returns and return accruals for, and clinical utility of GOHIBIC (vilobelimab) in its approved or authorized indications or for vilobelimab and any other product candidates, under an EUA and in the future if approved for commercial use in the U.S. or elsewhere; our ability to successfully implement The InflaRx Commitment Program, the success of our future clinical trials for vilobelimab’s treatment of COVID-19 and other debilitating or life-threatening inflammatory indications, including PG, and any other product candidates, including INF904, and whether such clinical results will reflect results seen in previously conducted pre-clinical studies and clinical trials; the timing, progress and results of pre-clinical studies and clinical trials of our product candidates and statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, the costs of such trials and our research and development programs generally; our interactions with regulators regarding the results of clinical trials and potential regulatory approval pathways, including related to our biologics license application submission for GOHIBIC (vilobelimab), and our ability to obtain and maintain full regulatory approval of vilobelimab or GOHIBIC (vilobelimab) for any indication; whether the FDA, or any comparable foreign regulatory authority will accept or agree with the number, design, size, conduct or implementation of our clinical trials, including any proposed primary or secondary endpoints for such trials; our expectations regarding the scope of any approved indication for vilobelimab; our ability to leverage our proprietary anti-C5a and C5aR technologies to discover and develop therapies to treat complement-mediated autoimmune and inflammatory diseases; our ability to protect, maintain and enforce our intellectual property protection for vilobelimab and any other product candidates, and the scope of such protection; our manufacturing capabilities and strategy, including the scalability and cost of our manufacturing methods and processes and the optimization of our manufacturing methods and processes, and our ability to continue to rely on our existing third-party manufacturers and our ability to engage additional third-party manufacturers for our planned future clinical trials and for commercial supply of vilobelimab and for the finished product GOHIBIC (vilobelimab); our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing; our ability to defend against liability claims resulting from the testing of our product candidates in the clinic or, if approved, any commercial sales; if any of our product candidates obtain regulatory approval, our ability to comply with and satisfy ongoing obligations and continued regulatory overview; our ability to comply with enacted and future legislation in seeking marketing approval and commercialization; our future growth and ability to compete, which depends on our retaining key personnel and recruiting additional qualified personnel; and our competitive position and the development of and projections relating to our competitors in the development of C5a and C5aR inhibitors or our industry; and the risks, uncertainties and other factors described under the heading “Risk Factors” in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

FAQ

When will InflaRx (IFRX) report the interim analysis for vilobelimab Phase 3 trial in pyoderma gangrenosum?

The interim analysis is expected by the end of May 2025, following the achievement of the 30-patient recruitment milestone.

What was InflaRx's (IFRX) cash position at the end of 2024?

InflaRx had €55.2 million in cash, cash equivalents and marketable securities as of December 31, 2024.

What are the expected market opportunities for INF904 in CSU and HS according to InflaRx (IFRX)?

InflaRx believes each indication (CSU and HS) has potential addressable markets of $1 billion or more for INF904.

When will InflaRx (IFRX) report topline Phase 2a data for INF904 in CSU and HS?

Topline data from the Phase 2a study is expected in summer 2025.

What was InflaRx's (IFRX) net loss for the full year 2024?

The company reported a net loss of €46.1 million, or €0.78 per ordinary share.